RuDo Logo
Talk to an adviser

PGIM India Healthcare Fund

Pharma and Healthcare · Direct plan · Growth

₹13.07

+₹0.13 (+1.00%) today

NAV on 20 Nov 2026Near its 52-week high

This fund +27.64%BSE Healthcare +19.35%past 5 days

Returns

Up to a year

PeriodThis fundBSE HealthcareRank
1 month+12.29%+11.49%5/19
3 months+4.56%+5.00%7/18
6 months+17.22%+11.71%3/18
This year+30.44%+21.57%3/18
1 year+27.64%+19.35%4/17

Longer term

This fundBSE Healthcare
TotalA yearA yearRank
2 years––+12.1%–
3 years––+21.6%–
5 years––+15.9%–
7 years––+22.0%–
10 years––+13.4%–
Since inception+30.70%+14.7%+9.6%–

₹1 lakh invested at the start (Dec 2024) is ₹1.31 lakh today.

From the plan's own NAV, to 20 Nov 2026. Rank 1 is best. Past returns are no guide to the future.

RiskWorst fall -14.5% · volatility 17.0% a year

Volatility, since launch

17.0%

BSE Healthcare 16.1%

Worst fall

-14.5%

Feb 2025, back by Jul 2025

Worst calendar year

-1.0%

2025

Up months

61%

last 3 years

Against other pharma and healthcare funds, last 3 years (worst fall: 5 years)

Yearly cost

= 0.98%

About average · average 1.10%

5 of 18

More measures ›

Sharpe ratio, 3 years

N/A

Return above the CRISIL Overnight Index per unit of volatility

Sortino ratio, 3 years

N/A

The same, counting only falls

Alpha vs BSE Healthcare

N/A

Yearly return beyond what its beta explains

Beta vs BSE Healthcare

N/A

Moves this much when the index moves 1%

Share of the index's rises

114%

In months the index rose

Share of the index's falls

95%

In months the index fell; lower is better

Over the last 3 years, from the fund's NAVs against the BSE Healthcare.

Where it ranksAgainst 19 pharma and healthcare funds

Category rank, year by year

In the top half of pharma and healthcare funds in 2 of 2 calendar years.

Top quarter in 2, bottom quarter in 0.

3/18

Rank in 2026 YTD

'17

N/A

'18

N/A

'19

N/A

'20

N/A

'21

N/A

'22

N/A

'23

N/A

'24

N/A

'25

Q1

'26

Q1

Each year ranks the pharma and healthcare funds by that year's return from their own Direct Growth NAV; Q1 is the top quarter. 2026 is year to date. The peer group is today's funds, so funds that closed or merged in earlier years are not counted. Past performance does not indicate future returns.

Where it ranks

among 19 pharma and healthcare funds, Direct plans

1 year

4 of 17

Top quarter

Lowest cost

5 of 18

Second quarter

Best over 3 years3 yearsCost
1HDFC Pharma and Healthcare Fund+123.0%1.04%
2SBI Healthcare Opportunities Fund+94.4%1.00%
3Mirae Asset Healthcare Fund+90.9%0.61%
4UTI Healthcare Fund+87.3%1.34%
5LIC MF Healthcare Fund+80.9%1.38%
14PGIM India Healthcare Fund this fund–0.98%

Every fund in the category computed from its own NAV the same way, to 20 Nov 2026. All Pharma and Healthcare funds ›

What stands out

What it holds

32 holdings · as of Aug 2026

  1. 1Divi'S Laboratories Ltd10.85%
  2. 2Sun Pharmaceutical Industries Ltd10.74%
  3. 3Torrent Pharmaceuticals Ltd8.86%
  4. 4Cash, TREPS and repo5.76%
  5. 5Max Healthcare Institute Ltd4.96%
  6. 6Ajanta Pharma Ltd4.83%
  7. 7Manipal Health Enterprises Ltd4.12%
  8. 8Mankind Pharma Ltd4.07%
  9. 9Rubicon Research Ltd4.01%
  10. 10Dr. Lal Pathlabs Ltd3.93%
Top 10: 62.1% of the fund
P/E 67.3 · Turnover 33% a yearCheck overlap with another fund ›

SIP returns of pharma and healthcare funds · All pharma and healthcare funds · Fund screener

About PGIM India Healthcare Fund Direct Plan Growth Option

PGIM India Healthcare Fund Direct Plan Growth Option is a Sector Specific - Pharma equity fund from PGIM India Asset Management Private Limited, launched on 3 Dec 2024. Its benchmark is the BSE Healthcare Index. The expense ratio is 0.98% a year. It manages ₹142 crore. The NAV was ₹13.07 on 20 Nov 2026.

Questions about PGIM India Healthcare Fund

What is the NAV of PGIM India Healthcare Fund Direct Growth?

The NAV of PGIM India Healthcare Fund Direct Growth was ₹13.07 on 20 Nov 2026. Mutual fund NAVs are published once a day, after markets close.

What are the returns of PGIM India Healthcare Fund Direct Growth?

PGIM India Healthcare Fund Direct Growth returned 27.6% over 1 year, to 20 Nov 2026, worked out from its own daily NAV. It returned more than the BSE Healthcare Index in 2 of 3 calendar years since 2024.

What is the expense ratio of PGIM India Healthcare Fund Direct Growth?

0.98% a year. It is taken from the fund's assets every day, so the NAV and every return shown are already after this cost.

Can NRIs in the UAE invest in PGIM India Healthcare Fund?

NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. PGIM India Mutual Fund does not accept investors living in the US or Canada, per its own documents checked on 15 Nov 2026. Rules change, so confirm with the fund house.

How are PGIM India Healthcare Fund gains taxed for NRIs?

India taxes gains on equity funds at 20% on units held 12 months or less, and at 12.5% on gains above ₹1.25 lakh a year on units held longer, plus cess and any surcharge. For NRIs the tax is deducted when units are redeemed. The UAE has no personal income tax, and the India UAE tax treaty may apply, so confirm your position with a tax adviser.

Rolling returns shows every period, not just the latest.

Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.

Investing from the UAE. NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. Some fund houses restrict residents of the US and Canada. India taxes equity fund gains at 20% on units held 12 months or less and 12.5% above ₹1.25 lakh a year after that, plus cess and any surcharge, deducted when an NRI redeems. The UAE has no personal income tax and the India UAE treaty may apply, so confirm your position with a tax adviser.

Data from RuDo Wealth fund analytics, NAV as of 20 Nov 2026; benchmark as named by PGIM India Asset Management Private Limited. India: RuDo Wealth Investment Advisory, SEBI Registered Investment Adviser, registration INA000019503. UAE: RuDo Digital Wealth, FSRA Financial Services Permission 220155, Category 3C (Retail), ADGM. General information, not a recommendation to buy or sell this fund. Past performance does not indicate future returns.